215 related articles for article (PubMed ID: 11364252)
1. Delavirdine (Rescriptor) approved.
James JS
AIDS Treat News; 1997 Apr; (No 269):1-3. PubMed ID: 11364252
[TBL] [Abstract][Full Text] [Related]
2. Delavirdine gets FDA approval. Food and Drug Administration.
AIDS Alert; 1997 Jun; 12(6):70. PubMed ID: 11364363
[TBL] [Abstract][Full Text] [Related]
3. Delavirdine gets the green light.
Vazquez E
Posit Aware; 1997; 8(3):18-9. PubMed ID: 11364419
[TBL] [Abstract][Full Text] [Related]
4. Delavirdine gains approval as second NNRTI for anti-HIV combination regimens.
Crit Path AIDS Proj; 1997; (No 32):29-30. PubMed ID: 11364439
[TBL] [Abstract][Full Text] [Related]
5. Delavirdine dilemma at the FDA. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1996 Dec; 10(12):4-5. PubMed ID: 11364017
[TBL] [Abstract][Full Text] [Related]
6. Delavirdine data: skewed or skewered?
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Feb; 3(2):42-6. PubMed ID: 11364099
[TBL] [Abstract][Full Text] [Related]
7. Delavirdine/protease inhibitor interactions.
Gilden D
GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
[TBL] [Abstract][Full Text] [Related]
8. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Mascolini M
AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine and delavirdine plus protease inhibitors.
GMHC Treat Issues; 1996 Apr; 10(4):8. PubMed ID: 11363709
[TBL] [Abstract][Full Text] [Related]
10. [New combination medications].
Agosto M
Sidahora; 1997; ():43-6. PubMed ID: 11364501
[TBL] [Abstract][Full Text] [Related]
11. Non-nucleoside reverse transcriptase inhibitors.
Bowers M
BETA; 1996 Jun; ():19-22. PubMed ID: 11363645
[TBL] [Abstract][Full Text] [Related]
12. Understanding the reverse transcriptase inhibitors in HIV.
Edmonds-Ogbuokiri J
Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Davey RT; Chaitt DG; Reed GF; Freimuth WW; Herpin BR; Metcalf JA; Eastman PS; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Boyle J; Coleman S; Cox SR; Wathen L; Daenzer CL; Lane HC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1657-64. PubMed ID: 8807058
[TBL] [Abstract][Full Text] [Related]
14. '96-'97 new drugs and the nominees for 1997 are...
Notes Undergr; 1997; (No 35):suppl 1-2. PubMed ID: 11364566
[TBL] [Abstract][Full Text] [Related]
15. A new class of anti-HIV drugs.
Treat Rev; 1996 Aug; (No 22):8-9. PubMed ID: 11363816
[TBL] [Abstract][Full Text] [Related]
16. Expanded access for delavirdine.
Posit Aware; 1996; 7(3):5-6. PubMed ID: 11363426
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
18. FDA approves first new class of HIV drugs. Food and Drug Administration.
AIDS Alert; 1996 Aug; 11(8):89. PubMed ID: 11363655
[TBL] [Abstract][Full Text] [Related]
19. HIV drug now approved for use with protease inhibitors.
Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335
[No Abstract] [Full Text] [Related]
20. Nonnucleoside reverse transcriptase inhibitors.
Murphy RL
AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
